Pharmaceuticals

Carbapenem-Based Antibiotics Industry Overview 2025: Growth Projections and Market Trends

November 11, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

#What Are The Current (2025) And Forecast (2029) Sizes Of The Carbapenem-Based Antibiotics Market?

The market size for carbapenem-based antibiotics has experienced consistent growth in recent years. This market is projected to expand from $4.6 billion in 2024 to $4.78 billion by 2025, at a compound annual growth rate (CAGR) of 3.8%. The growth observed in the historic period is attributable to factors such as epidemics and pandemics, an increase in chronic diseases, the expansion of healthcare infrastructure, rapid urbanization, and various natural disasters and health emergencies.

The carbapenem-based antibiotics market size is projected to demonstrate strong growth over the next few years, expanding to $5.97 billion by 2029 at a compound annual growth rate (CAGR) of 5.7%. This anticipated growth during the forecast period can be attributed to an increased incidence of hospital-acquired infections, the emergence of multi-drug resistant strains, a growing aging population, a rise in surgical procedures, the proliferation of infectious diseases, and changing demographics. Major trends expected in the forecast period include enhanced supply chain resilience and security, the development of alternative treatments, a shift towards outpatient healthcare settings, increasing awareness of antimicrobial stewardship, and the adoption of precision medicine approaches.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12035&type=smp

Which Drivers Are Shaping The Carbapenem-Based Antibiotics Industry’s Market Share?

A rising occurrence of bacterial infections is anticipated to propel the future expansion of the carbapenem-based antibiotics market. Bacterial infections originate from bacteria, microscopic organisms capable of invading the body and causing various diseases and symptoms. Carbapenem-based antibiotics are utilized for managing severe or multidrug-resistant bacterial infections, including those caused by gram-positive and gram-negative bacteria. For instance, in July 2024, a report published by the Centers for Disease Control and Prevention, a US-based government agency, highlighted that during 2023, 78% of all bacterial infections in the historic catchment area were diagnosed by CIDTs, with 46% identified exclusively using CIDTs. Consequently, the increased incidence of bacterial infections serves as a driver for the growth of the carbapenem-based antibiotics market.

What Are The Different Segment Classifications Within The Carbapenem-Based Antibiotics Market?

The carbapenem-based antibiotics market covered in this report is segmented –

1) By Type: Meropenem, Imipenem, Doripenem, Tebipenem, Other Types

2) By Indication: Intra-abdominal Infections, Urinary Tract Infections, Pneumonia, Bacterial Meningitis, Skin And Skin Structure Infections, Acute Pelvic Infections, Prophylaxis of Surgical Site Infection, Respiratory Tract Infections, Gynecological Infections, Other Indications

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Meropenem: Meropenem Injection, Meropenem and Vaborbactam Combination, Meropenem for Pediatric Use

2) By Imipenem: Imipenem and Cilastatin Combination, Imipenem and Relebactam Combination, Imipenem Monotherapy

3) By Doripenem: Doripenem Injection, Doripenem for Complicated Infections

4) By Tebipenem: Tebipenem for Oral Administration, Tebipenem Pediatric Formulations, Tebipenem for Resistant Infections

5) By Other Types: Ertapenem, Panipenem, Faropenem, Combinations with Beta-Lactamase Inhibitors

Which Market Trends Are Creating New Opportunities In The Carbapenem-Based Antibiotics Industry?

Product innovation stands out as a significant and growing trend within the carbapenem-based antibiotics market. Leading entities within the carbapenem-based antibiotics market are developing new products to maintain their competitive edge. An illustrative example is the launch of a groundbreaking antibiotic subscription program in August 2024 by the National Health Service, a UK-based Government department, partnering with the pharmaceutical industry to combat antimicrobial resistance (AMR). This novel approach, revealed on August 12, 2024, enables drug manufacturers to collect consistent annual payments, reaching up to £20 million per drug, irrespective of prescription volume, thereby eliminating motivations for excessive use. Valued at roughly £1.9 billion over a 16-year period, the initiative seeks to stimulate the creation of novel antibiotics by guaranteeing financial stability for pharmaceutical firms. Coming after a successful trial phase, this program integrates into the UK’s wider strategy to address AMR, a major global health risk that could result in millions of fatalities by 2050 if neglected. The NHS intends to give precedence to products designed to combat crucial pathogens designated by the World Health Organization, thereby reaffirming its dedication to ethical antibiotic management and promoting advancements in antibiotic creation.

Which Major Firms Are Strengthening Their Position In The Carbapenem-Based Antibiotics Industry?

Major companies operating in the carbapenem-based antibiotics market include Pfizer Inc., Merck & Co. Inc., Fresenius Kabi LLC, GlaxoSmithKline Plc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., AstraZeneca plc, Meiji Holdings Co. Ltd., Sandoz International GmbH, Sumitomo Dainippon Pharma Co. Ltd., Shionogi & Co Ltd., Aurobindo Pharma Ltd., Acurx Pharmaceuticals LLC, Daewoong Pharmaceutical Co. Ltd., CeramTec GmbH, ACS Dobfar S.p.A, JW Pharmaceutical Corp, Centrient Pharmaceuticals Co, Spero Therapeutics Inc., Kopran Limited, Savior Lifetec Corporation, Flagship Biotech International Pvt. Ltd., Iterum Therapeutics plc, Cam Carbapenem-based antibiotics BV, Intelicure Lifesciences, Ikeda Corporation

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/carbapenem-based-antibiotics-global-market-report

How Is Carbapenem-Based Antibiotics Market Demand Varying Across Different Regions?

North America was the largest region in the Carbapenem-Based Antibiotics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the carbapenem-based antibiotics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Carbapenem-Based Antibiotics Market Report:

https://www.thebusinessresearchcompany.com/customise?id=12035&type=smp

Browse Through More Reports Similar to the Global Carbapenem-Based Antibiotics Market 2025, By The Business Research Company

Motor Vehicle And Parts Dealers Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/motor-vehicle-and-parts-dealers-global-market-report

Automobiles And Heavy Equipment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/automobiles-and-heavy-equipment-global-market-report

Electric Motor And Generator Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/electric-motor-and-generator-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795